September/October 2019

A Review of Dupilumab

October 27, 2019

Clinical Insights

Dupixent is the first FDA-approved medicine for adults with chronic rhinosinusitis with nasal polyposis and the only approved therapy shown to shrink nasal polyp size and improve the signs and symptoms of the associated chronic rhinosinusitis.

Biologics Expand Treatment Options in Psoriatic Disease

October 26, 2019

Features

At the recent National Association of Specialty Pharmacy Annual Meeting and Expo in Washington, DC, Jamie McConaha, PharmD, NCTTB, BCACP, CDE, associate professor of pharmacy practice at Duquesne University Mylan School of Pharmacy, and April Jones, PharmD, CSP, clinical specialty pharmacist at Vanderbilt University Medical Center, engaged specialty pharmacists in a concise but thorough presentation on psoriasis and psoriatic arthritis.

A Welcome Back for NASP Members at Annual Meeting

October 24, 2019

Features

The 2019 National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo began with a message of collaboration by the organization’s outgoing president, Carmine DeNardo, RPh, president and CEO of ReCept.

FDA Biosimilar Action Plan Presented at NASP 2019 Annual Meeting

October 22, 2019

Features

During the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo, Ron Lanton III, Esq, reviewed the FDA Biosimilars Action Plan, its implications for the biosimilar marketplace, recent legislation set to influence the biosimilar pathway and drug accessibility, and the future of the biosimilar market.

NASP Session Explores FDA-Approved Treatment Options for AML, MM

October 19, 2019

Features

In "2019 State of Care: Oncology/ Hematology,” during the National Association of Specialty Pharmacy 2019 Annual Meeting and Expo in Washington, DC, Joseph Barone, PharmD, BCOP, examined current standards of care for acute myeloid leukemia (AML) and multiple myeloma (MM) and identified new agents approved over the past year.

Product Theater: Vemlidy for Hepatitis B

October 18, 2019

Features

Chronic hepatitis B virus (HBV), which affects an estimated 862,000 individuals in the United States, is caused by long-term infection with the virus and can lead to serious liver damage.

High-Touch Specialty Pharmacy Services Improve Migraine Medication Access and Affordability

October 17, 2019

Features

The underlying purpose of a study presentation that won the Top Poster Award at the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo in Washington, DC, was to assess whether high-touch, clinic-based specialty pharmacy services could positively affect the affordability of self- and provider-administered migraine medications for patients.